The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, J. H.
Right arrow Articles by Im, S. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, J. H.
Right arrow Articles by Im, S. Y.
The Journal of Immunology, 2001, 166: 5139-5144.
Copyright © 2001 by The American Association of Immunologists

Platelet-Activating Factor-Induced Early Activation of NF-{kappa}B Plays a Crucial Role for Organ Clearance of Candida albicans1

Jung Hwa Choi*, Hyun Mi Ko*, Jung-Woo Kim*, Hern-Ku Lee{dagger}, Sang Seop Han{ddagger}, Soon-Bai Chun* and Suhn Young Im2,*

* Department of Biological Sciences, College of Natural Sciences, Chonnam National University, Kwangju, Korea; {dagger} Department of Immunology and Institute for Medical Sciences, Chonbuk National University Medical School, Chonju, Republic of Korea; and {ddagger} Korean Research Institute of Chemical Technology, Daejon, Korea


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In this study, we have investigated the mechanisms underlying organ susceptibility to candida infection. Infection of BALB/c mice with Candida albicans led to both an early (1–8 h) and late (24–48 h) activation of NF-{kappa}B in the organs resistant to C. albicans, including the lung and spleen. In susceptible organs such as the kidneys, early activation of NF-{kappa}B was not observed. The kinetics of TNF-{alpha} mRNA expression paralleled those of NF-{kappa}B activation in all organs examined. Blocking the effects of endogenous platelet-activating factor (PAF) by pretreatment with the PAF antagonist BN50739 or antioxidants significantly reduced the early activity of NF-{kappa}B and TNF-{alpha} mRNA expression, and increased the recovery of C. albicans in the lung and spleen. Importantly, administration of PAF 5 min prior to the infection resulted in the appearance of early activities of NF-{kappa}B and TNF-{alpha} mRNA expression, followed by a nearly complete clearance of the organisms in the kidneys. Pretreatment with anti-TNF-{alpha} Ab resulted in an enhanced susceptibility to C. albicans, and the PAF-mediated resistance was abrogated by anti-TNF-{alpha} in all organs examined. These data indicated that endogenously produced PAF in response to C. albicans is a key molecule involved in the early activation of NF-{kappa}B, which, in turn, renders the organ resistant to the fungus by promoting the production of anti-candidal proinflammatory cytokines such as TNF-{alpha}. Susceptible organs, including the kidneys, lack the capacity to generate a sufficient PAF-induced early NF-{kappa}B response.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In patients with impaired host defenses, the yeast Candida albicans is a major opportunistic fungal pathogen which can cause life-threatening infections of the internal organs. Specifically, individuals with AIDS or those undergoing organ transplantation are highly vulnerable (1, 2). The kidneys appear to be particularly susceptible to C. albicans and renal failure is the major cause of death in systemic candida infection (3, 4). However, the molecular and cellular events underlying the susceptibility of kidneys to C. albicans are unknown.

Platelet-activating factor (PAF),3 which is produced by a variety of inflammatory cells, is a potent lipid-derived first messenger involved in cellular activation, fertilization, intracellular signaling, apoptosis, and diverse inflammatory reactions (5, 6, 7, 8). We have recently reported that PAF has a protective role in systemic murine candida infection and that the effect of PAF appears to be mediated by TNF-{alpha} (9). PAF is released immediately in response to an inflammatory stimulus and induces TNF-{alpha} expression through the activation of the inducible transcription factor NF-{kappa}B (10). NF-{kappa}B plays a central role in the induction of genes encoding proinflammatory cytokines and growth factors (e.g., TNF-{alpha}, IL-1, and G-CSF) (11, 12), all of which can confer protective activity against systemic C. albicans infection (13, 14, 15). It is possible, therefore, that PAF-induced NF-{kappa}B activation plays a role in the pathogenesis of organ-specific susceptibility to C. albicans infection.

In this study, we investigated the role of NF-{kappa}B activation in the organ resistance to systemic candida infection and the underlying mechanism for NF-{kappa}B activation. We found that clearance of C. albicans in an organ is exclusively dependent upon the PAF-induced early activation of NF-{kappa}B in the organ. This may be a general protective mechanism for infections in which cellular immunity plays a major role.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
C. albicans

C. albicans NIH A-207 was kindly provided by Professor Hideoki Ogawa (University of Juntendo, Tokyo, Japan). C. albicans was grown to stationary phase at 28°C under slight agitation in Sabouraud dextrose broth (BBL Microbiology Systems, Cockeysville, MD). After a 24-h culture, cells were harvested by centrifugation (2000 x g), washed twice in PBS, diluted to the desired density, and injected i.v. via the tail vein in a volume of 0.1 ml.

Animals

Specific pathogen-free female BALB/c were provided by the Korean Institute of Chemistry Technology (Daejon, Korea) and were kept in our animal facility for 1–2 wk before use. All mice were used at 8–10 wk of age.

Reagents

Water-soluble PAF (1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine), (+)-{alpha}-tocopherol acid succinate (Vit. E), and N-acetyl-L-cysteine (NAC) were purchased from Sigma (St. Louis, MO). The PAF antagonist BN50739 (batch 51-884, Mr 596.2, 50 mg/ml in DMSO), a ginkoglide-derived synthetic PAF analogue, was a gift from Piere Braquet (Institute Henri Beaufour, Le Plessis Robinson, France). The PAF antagonist BN50739 is a synthetic PAF analogue counteracting the effects of endogenous PAF by inhibiting PAF binding to its receptor and the subsequent cellular responses. The efficacy of the BN50739 as a PAF antagonist has been evaluated in previous studies (9, 10, 16, 17). Polyclonal anti-murine TNF-{alpha} Ab was prepared from a New Zealand White rabbit as previously described (9). The IgG fraction from immune or preimmune serum was purified by protein G chromatography (Pierce, Rockford, IL).

Quantification of C. albicans

Lung, spleen, and kidneys from individual mice were removed aseptically and homogenized with 0.2 ml of PBS. The number of viable CFU in the specimens was determined by dilution plating on Sabouraud dextrose agar (BBL Microbiology Systems).

RT-PCR

RNA was prepared as previously described (10, 16). Reverse transcription was performed using 1 µl of total RNA in a 10-µl reaction mixture (Promega, Madison, WI) containing oligo(dT)15 and avian myeloblastosis virus reverse transcriptase. cDNA (1 µl) was amplified by PCR in a thermal cycler Perkin-Elmer System 2400 (Norwalk, CT) (denaturation for 1 min at 94°C, annealing for 1 min at 60°C, and elongation for 40 s at 72°C) using TNF-{alpha} (30 cycles) or {beta}-actin primers (23 cycles). The primers used in these analysis are as follows: {beta}-actin, 5'-GGG TCA GAA CTC CTA TG-3' and 5'-GTA ACA ATG CCA TGT TCA AT-3'; TNF-{alpha}, 5'-CCT GTA GCC CAC GTC GTA GC-3' and 5'-TTG ACC TCA GCG CTG AGT TG-3'.

Gel shift assay

The nuclear extracts were prepared from the lungs as described previously (10, 16). To inhibit endogenous protease activity, 1 mM PMSF was added. As a probe for the gel retardation assay, an oligonucleotide containing the Ig{kappa}-chain binding site ({kappa}B, 5'-CCG GTT AAC AGA GGG GGC TTT CCG AG-3') was synthesized. The two complementary strands were annealed and labeled with [{alpha}-32P]dCTP. Labeled oligonucleotides (10,000 cpm), 10 µg of nuclear extracts, and binding buffer (10 mM Tris-HCl (pH 7.6), 500 mM KCl, 10 mM EDTA, 50% glycerol, 100 ng of poly(dI · dC), and 1 mM DTT) were incubated for 30 min at room temperature in a final volume of 20 µl. The reaction mixture was analyzed by electrophoresis on a 4% polyacrylamide gel in 0.5x Tris-borate buffer. Specific binding was controlled by competition with a 50-fold excess of cold {kappa}B or cAMP response element oligonucleotide.

Statistical analysis

The data are represented as the mean ± SE of multiple determinations from an experiment. Statistical significance was determined by Student’s t test when two data sets were analyzed or, alternatively, by ANOVA followed by the appropriate post hoc test for multiple data sets with the statistical software StatView (version 4.5; SAS Institute, Cary, NC). All experiments were conducted two or more times. Reproducible results were obtained and representative data are therefore shown in the figures.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Early activation of NF-{kappa}B is absent in the kidneys of C. albicans-infected mice

The kinetics of NF-{kappa}B activation in resistant (lung and spleen) and susceptible (kidneys) organs to C. albicans was examined for 5 days following infection. As shown in Fig. 1Go, there were marked differences in the kinetics of NF-{kappa}B activation in these organs. The early (1–8 h) and late (24–48 h) activation of NF-{kappa}B was evident in the lung and spleen (Fig. 1Go, A and B). In the kidneys, however, the early activation of NF-{kappa}B was absent. NF-{kappa}B activation in the kidney was seen after 24-h postcandida infection (Fig. 1C). TNF-{alpha} is an important cytokine involved in resistance to C. albicans infection (9, 13), and its expression is tightly regulated by NF-{kappa}B activity (10, 11, 12). Time kinetics of TNF-{alpha} mRNA expression paralleled the kinetics of NF-{kappa}B activation in all organs examined (Fig. 1Go). Quantitative cultures revealed that the numbers of C. albicans in the lung and spleen decreased from day 1. By contrast, growth of the organisms in the kidneys increased from day 1. By days 3–5, the fungal burden in the kidneys was 10- to 1000-fold higher than that of other organs (Fig. 2Go). These data suggest that the early activation of NF-{kappa}B is related to the early clearance of C. albicans in an organ-specific manner.



View larger version (46K):
[in this window]
[in a new window]
 
FIGURE 1. Kinetics of NF-{kappa}B activation and TNF-{alpha} mRNA expression in the lung (A), spleen (B), and kidneys (C) in C. albicans-infected mice. Mice were infected i.v. with 5 x 106 C. albicans on day 0. Nuclear extracts prepared from the organs at the times indicated were incubated with 32P-labeled {kappa}B oligonucleotide and electrophoresed on a 4% polyacrylamide gel. A 50-fold excess of {kappa}B or an irrelevant oligonucleotide (cAMP response element (CRE)) was added as competitor. TNF-{alpha} mRNA expression was measured by RT-PCR as described in Materials and Methods. n = 3 animals for each group. A representative of three to five independent experiments is shown.

 


View larger version (20K):
[in this window]
[in a new window]
 
FIGURE 2. Organ differences in the recovery of C. albicans. Mice were infected i.v. with 5 x 106 C. albicans on day 0. Recovery of C. albicans from the organs on days 1, 3, and 5 were determined as described in Materials and Methods. n = 5 animals for each group. A representative of three to five independent experiments is shown.

 
PAF is involved in the early activation of NF-{kappa}B and efficient clearance of C. albicans in the lung and spleen

Based on the facts that PAF is released immediately in response to an inflammatory stimulus (10) and is a potent inducer of NF-{kappa}B activation (10, 18, 19), we investigated whether PAF is involved in the early activation of NF-{kappa}B seen in the lung and spleen. Blocking of endogenous PAF by pretreatment with the PAF antagonist BN50739 resulted in the inhibition of most of the early NF-{kappa}B activation and TNF-{alpha} mRNA expression in the lung and spleen. In parallel, pretreatment with the PAF antagonist resulted in a progressive increase (2- to 5-fold) in the recovery of C. albicans over the 3 days after infection in the lung and spleen (Fig. 3Go, A and B). NF-{kappa}B activation and TNF-{alpha} mRNA expression were not significantly altered by pretreatment with BN50739 in the kidneys (Fig. 3C), but a slight increase in the recovery of C. albicans was observed. We further clarified the role of early NF-{kappa}B activation by blocking NF-{kappa}B activity using the antioxidants Vit. E and NAC. Reactive oxygen intermediates are strong inducers of NF-{kappa}B (20, 21). We have recently demonstrated that antioxidants selectively inhibited PAF-induced activation of NF-{kappa}B (22). The efficacy of antioxidants in blocking LPS-induced NF-{kappa}B activation was determined in preliminary experiments (data not shown). Pretreatment of the mice with antioxidants before infection exerted similar effects as did BN50739 pretreatment (Fig. 4Go). These data indicated that PAF is involved in the early activation of NF-{kappa}B, which is critical for organ-specific clearance of C. albicans.



View larger version (29K):
[in this window]
[in a new window]
 
FIGURE 3. Effect of blocking of endogenous PAF activity on NF-{kappa}B activation, TNF-{alpha} mRNA expression, and fungal recovery. BN50739 (200 µg/mouse) were injected i.p. 1 h and 30 min before C. albicans (5 x 106/mouse, i.v.) infection. Recovery of C. albicans from the organs (A–C) was performed on day 3. n = 3–5 animals for each group. A representative of three to five independent experiments is shown. *, p < 0.05; **, p < 0.01 vs control group.

 


View larger version (34K):
[in this window]
[in a new window]
 
FIGURE 4. Antioxidants inhibit the early activation of NF-{kappa}B, TNF-{alpha} mRNA expression, and fungal recovery in the lung and spleen (A and B) but not in the kidneys (C) in C. albicans-infected mice. Vit. E (0.5 mg/mouse) was injected i.p. 24 and 2 h before C. albicans (5 x 106/mouse, i.v.) infection. NAC (10 µg/mouse) was injected i.p. 2 h before C. albicans infection. Recovery of C. albicans from the organs was performed on day 3. n = 3–5 animals for each group. A representative of three to five independent experiment is shown. *, p < 0.05 vs control group.

 
Appearance of the early activity of NF-{kappa}B and efficient clearance of C. albicans in the kidneys by exogenous PAF

Administration of exogenous PAF has been reported to protect mice from death and reduce the growth of C. albicans in the kidneys (9). Thus, we examined how exogenous PAF regulates NF-{kappa}B activation and fungal burden in the kidneys. Administration of PAF 5 min before the infection resulted in the early activation of NF-{kappa}B and early expression of TNF-{alpha} mRNA, followed by efficient clearance of the organisms in the kidneys (Fig. 5A). The fungal burden in the kidneys after PAF treatment was <1% of control (230 x 102 vs 2 x 102). Exogenous PAF exerted protective effects in the lung and spleen, albeit to a much lesser degree than that of exogenous PAF in the kidneys; it increased NF-{kappa}B activation and TNF-{alpha} mRNA expression at the earlier time point and slightly decreased the recovery of C. albicans in the lung and spleen (Fig. 5Go, B and C). The PAF-induced early activation of NF-{kappa}B, TNF-{alpha} mRNA expression, and efficient clearance of the fungus were completely blocked by either BN50739 or Vit. E (Fig. 6Go) in the kidney, indicating that early activation of NF-{kappa}B and efficient clearance of the fungus in the kidneys are an exclusively PAF-dependent process. These data further support the potential involvement of PAF in the early activation of NF-{kappa}B following C. albicans infection and support the hypothesis that failure to efficiently clear C. albicans in the kidneys is due to the absence of PAF-induced early activation of NF-{kappa}B.



View larger version (29K):
[in this window]
[in a new window]
 
FIGURE 5. Administration of exogenous PAF induces early activation of NF-{kappa}B, TNF-{alpha} mRNA expression, and efficient clearance of C. albicans in the kidneys. PAF (1 µg/mouse) was administered i.p. 5 min before C. albicans (5 x 106/mouse, i.v.) infection. Recovery of C. albicans from the organs (A–C) was performed on day 3. n = 3–5 animals for each group. A representative of three to five independent experiments is shown. *, p < 0.05; **, p < 0.005 vs control.

 


View larger version (27K):
[in this window]
[in a new window]
 
FIGURE 6. Exogenous PAF-induced early activation of NF-{kappa}B and efficient clearance of the fungus are blocked by PAF antagonist (A) or Vit. E (B). BN50739 (200 µg/mouse) was injected i.p. 1 h and 30 min before C. albicans (5 x 106/mouse, i.v.) infection. Vit. E (0.5 mg/mouse) was injected i.p. 24 and 2 h before C. albicans infection. PAF (1 µg/mouse) was administered i.p. 5 min before C. albicans infection. Recovery of C. albicans from the kidneys was performed on day 3. n = 3–5 animals for each group. A representative of two independent experiment is shown. *, p < 0.005 vs control group; **, p < 0.005 vs PAF-injected group.

 
Effect of TNF-{alpha} inhibition on the resistance to C. albicans and PAF-induced enhanced resistance

To elucidate the efficacy of NF-{kappa}B-dependent cytokine, we examined the effect of TNF-{alpha} inhibition on clearances of C. albicans in the various organs by using anti-TNF-{alpha} polyclonal Ab. Administration of anti-TNF-{alpha} 10 min before C. albicans infection resulted in an enhanced susceptibility to C. albicans (Fig. 7A). The anti-TNF-{alpha}, but not control Ab, pretreatment increased the number of the organism in the kidneys from (7.8 ± 1.2) x 104 to (14.8 ± 2.7) x 104 CFU (*, p < 0.05). Furthermore, it also increased the fungal recovery in the lung from (4.9 ± 1.1) x 103 to (9.2 ± 1.7) x 103 CFU (*, p < 0.05) and in the spleen from (6.4 ± 1.3) x 103 to (10.8 ± 2.0) x 103 CFU (*, p < 0.05), supporting that a protective effect in candidiasis is mediated, at least in part, by TNF-{alpha}. We next examined the effect of TNF-{alpha} on PAF-induced enhanced resistance. As shown in Fig. 7B, anti-TNF-{alpha} abrogated the majority of PAF-induced enhanced resistance, suggesting that the PAF-induced protection is mediated by TNF-{alpha}.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We recently reported that administration of PAF following a lethal challenge of C. albicans protects mice from death and reduced the growth of organisms in the kidneys through the induction of TNF-{alpha} (9). The data of the present study demonstrated that the organ-specific protective effect of PAF against systemic candidiasis was due to its ability to induce the early activation of NF-{kappa}B. This process, in turn, inhibited the growth of C. albicans by promoting the production of proinflammatory cytokines such as TNF-{alpha}. The important difference between organs resistant to C. albicans such as lung and spleen and a susceptible organ such as the kidney was the kinetics of NF-{kappa}B activation as well as TNF-{alpha} mRNA expression. NF-{kappa}B activation and TNF-{alpha} mRNA expression occurred 1–2 h after C. albicans infection only in resistant, but not in susceptible organs. These results suggest that the early activation of NF-{kappa}B may determine the resistance to C. albicans within a specific organ.

A key element necessary for the early activation of NF-{kappa}B was determined to be the lipid-derived mediator PAF. The presence of PAF and subsequent early activation of NF-{kappa}B is necessary for limiting or suppressing C. albicans growth. This conclusion came from the observations that 1) the PAF antagonist BN50739 significantly abrogated the early activation of NF-{kappa}B as well as the early expression of TNF-{alpha} mRNA, followed by a 2- to 5-fold increase in the recovery of C. albicans in the lung and spleen; and 2) blocking of early activity of NF-{kappa}B using the antioxidants, Vit. E and NAC, showed comparable effects to those of BN50739. In this study, we used Vit. E and NAC as inhibitors of NF-{kappa}B activation. Antioxidants have been previously reported to selectively inhibit the ability of PAF to activate NF-{kappa}B-activating activity (22). Thus, the inhibition of PAF-induced early activation of NF-{kappa}B as well as efficient clearance of C. albicans by Vit. E and NAC indicated that PAF exerted its effect through the generation of reactive oxygen intermediates.

The administration of exogenous PAF resulted in the appearance of the early NF-{kappa}B activation as well as early TNF-{alpha} mRNA expression and efficient clearance of C. albicans in the kidneys. These effects were blocked by the PAF antagonist BN50739 or Vit. E. These data clearly indicated that the protective effect of exogenous PAF could be attributed to its ability to induce early NF-{kappa}B activation within the susceptible kidneys. However, much fewer alterations of these end points were seen in the lung and spleen by the administration of exogenous PAF. Thus, it seems likely that the PAF-mediated NF-{kappa}B activation process is particularly important in the kidneys, whereas other protective mechanism rather than PAF-mediated NF-{kappa}B-dependent protection may exist in the lung and spleen.

The mechanism underlying organ differences in PAF-mediated early activation of NF-{kappa}B is unclear. Since PAF is released or produced largely from inflammatory cells, it seems likely that organ-specific tissue macrophages represent the source of endogenous PAF in response to C. albicans. It is possible that the amount of PAF produced from tissue macrophages is not sufficient in susceptible organs to induce the early NF-{kappa}B activation. An impaired NF-{kappa}B response in the kidneys cannot, however, be responsible for the lack of C. albicans clearance since exogenous PAF administration resulted in NF-{kappa}B activation similar to what was observed in the lung and spleen. In contrast, much fewer changes in the level of NF-{kappa}B activation and fungal recovery in the lung and spleen occurred following exogenous PAF administration. Such findings suggests that endogenously produced PAF in the lung and spleen following infection contributes to the almost maximum protective effect. It is likely, therefore, that the amount of PAF produced endogenously in response to C. albicans in an organ may be the most important factor determining the level of resistance against the organisms. In systemic candidasis, the heart shows only minor lesions in normal mice. We examined the fungal recovery and NF-{kappa}B activation in the heart. The CFU recovered from the heart was much less (comprising 0.1–1%) than those from the other organs, and kinetic study revealed that very weak NF-{kappa}B activation was seen 24 h postinfection (data not shown). Although we do not know exactly the reason of low fungal recovery despite very weak NF-{kappa}B activation in the heart, this may be due to the fact that, in contrast to other organs which contain many mononuclear phagocytic cells such as lung, liver, spleen, and kidneys, there are very few tissue macrophages in the heart. Given the entry of the fungus into an organ is achieved by uptake of the fungus by tissue macrophages and intracellular killing activity of the cells plays an important role in host defenses against fungal diseases, it is possible that the heart is infected by much fewer C. albicans as compared to other organs. Alternatively proinflammatory cytokines such as IL-6 and IL-10 produced by cardiomyocytes (23, 24) may influence the growth of the organism.

NF-{kappa}B is normally present in the cytosol as part of an inactive complex that includes inhibitory proteins known as I{kappa}Bs. Phosphorylation of I{kappa}Bs by a variety of inducers triggers their degradation and induced dissociation of NF-{kappa}B from I{kappa}B followed by translocation of NF-{kappa}B is then free to translocate to the nucleus where it transactivates the expression of various proinflammatory cytokine genes (11, 12). Thus, the critical role for NF-{kappa}B activity in the resistance to C. albicans implies that anti-candidal cytokines under the transcriptional regulation by NF-{kappa}B are involved in the process. Cytokines under NF-{kappa}B-dependent regulation includes TNF-{alpha}, IL-1, and G-CSF (11, 12), all of which can confer protective activity against systemic C. albicans infection (13, 14, 15). TNF-{alpha} plays an important role in host resistance to infections caused by various microorganisms including C. albicans (25, 26), and TNF-{alpha} is a key molecule in PAF-induced protection against C. albicans (9). In the present study, we observed that there was always a complete correlation between the early activation of NF-{kappa}B and the early expression of the TNF-{alpha} gene, strongly suggesting that the potential protective effect of NF-{kappa}B against the organisms is attributed to the early production of NF-{kappa}B-dependent cytokines such as TNF-{alpha}.

It is presently unclear by what specific mechanism the early NF-{kappa}B activation and subsequent TNF-{alpha} expression exert an anti-candidacidal effect. Given that TNF-{alpha} and G-CSF have been reported to enhance host resistance to disseminated candidiasis through recruitment of neutrophils to the site of infection (15, 27), we determined whether exogenous PAF-induced enhanced clearance of C. albicans in the kidneys was mediated through neutrophil recruitment. This possibility was unlikely, however, because no evidence of cellular infiltration was found in these organs up to 3 days after infection (data not shown). Alternatively, exogenous PAF may exert its protective effect through enhancing candidacidal activity of tissue macrophages in the kidneys. This issue is currently under investigation.

In summary, our data suggest that endogenously produced PAF in response to C. albicans in an organ is a key mediator in the early activation of NF-{kappa}B. The activation of NF-{kappa}B, in turn, renders the organ resistant to the fungus by promoting the production of anti-candidal proinflammatory cytokines such as TNF-{alpha}. Susceptible organs, such as the kidney, to C. albicans is attributed to the inability of the organs to undergo this process. To our knowledge, this is the first report revealing the mechanism by which organ susceptibility in candida infection occurs and may provide a fundamental protective mechanism against infectious diseases caused by intracellular pathogens in which cellular immunity plays a major role.



View larger version (42K):
[in this window]
[in a new window]
 
FIGURE 7. Inhibition of resistance to C. albicans infection (A) and PAF-induced enhanced resistance (B) by administration of anti-TNF-{alpha} Ab. Two milligrams of anti-TNF-{alpha} IgG or control IgG was given i.p. 10 min before C. albicans (5 x 106/mouse, i.v.) infection. PAF (1 µg/mouse) was administered i.p. 5 min before C. albicans infection. Recovery of C. albicans from the organs was performed on day 3. n = 3–5 animals for each group. A representative of two independent experiments is shown. *, p < 0.005 vs control IgG-treated group; **, p < 0.005 vs PAF-injected group.

 

    Acknowledgments
 
We thank Dr. Jon. D. Hennebold for his critical review and reading of this manuscript.


    Footnotes
 
1 This work was supported by Grant 1999-015-D10101 from the Korea Research Foundation. Back

2 Address correspondence and reprint requests to Dr. Suhn-Young Im, Department of Biological Sciences, College of Natural Sciences, Chonnam National University Kwangju 500-757, Republic of Korea. Back

3 Abbreviations used in this paper: PAF, platelet-activating factor; Vit. E, (+)-{alpha}-tocopherol acid succinate; NAC, N-acetyl-L-cysteine. Back

Received for publication August 20, 2000. Accepted for publication February 14, 2001.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Klein, R. S., C. A. Harris, C. B. Small, B. Moll, M. Lesser, G. H. Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:354.[Abstract]
  2. Bodey, G. P.. 1984. Candidiasis in cancer patients. Am. J. Med. 77:(Suppl. 4D):13.[Medline]
  3. Odds, F. C.. 1988. Candida and Candidosis 2nd Ed. Balliere Tindall, London.
  4. Parker, J. C. J., J. J. McCloskey, K. V. Solanki, N. L. Goodman. 1976. Candidosis: the most common postmortem cerebral mycosis in an endemic fungal area. Surg. Neurol. 6:123.[Medline]
  5. Fukuda, A. I., K. F. Breuel. 1996. Effect of platelet-activating factor on embryonic development and implantation in the mouse. Hum. Reprod. 11:2746.[Abstract/Free Full Text]
  6. Shukla, S. D.. 1992. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J. 6:2296.[Abstract]
  7. Buttke, T. M., P. A. Sandstrom. 1995. Redox regulation of programmed cell death in lymphocytes. Free Radical Res. 22:389.[Medline]
  8. Braquet, P., L. Touqui, T. Y. Shen, B. B. Vargaftig. 1987. Perspectives in platelet-activating factor research. Pharmacol. Rev. 39:97.[Medline]
  9. Im, S. Y., J. H. Choi, H. M. Ko, S. J. Han, S. B. Chun, H. K. Lee, T. Y. Ha. 1997. A protective role of platelet-activating factor in murine candidiasis. Infect. Immun. 65:1321.[Abstract]
  10. Im, S. Y., S. J. Han, H. M. Ko, J. H. Choi, S. B. Chun, D. G. Lee, T. Y. Ha, H. K. Lee. 1997. Involvement of nuclear factor-{kappa}B in platelet-activating factor-mediated tumor necrosis factor-{alpha} expression. Eur. J. Immunol. 27:2800.[Medline]
  11. Baeuerle, P. A., D. Baltimore. 1988. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-{kappa}B transcription factor. Cell 53:211.[Medline]
  12. Kopp, E., S. Ghosh. 1994. NF-{kappa}B and Rel proteins in innate immunity. Adv. Immunol. 58:1.
  13. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, M. A. Gordon. 1994. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect. Immun. 62:2761.[Abstract/Free Full Text]
  14. Van’t, M. A., J. W. Wout, J. W. Van der Meer, M. Barza, C. A. Dinarello. 1988. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur. J. Immunol. 18:1143.[Medline]
  15. Kullberg, B. J., M. G. Netea, J. H. Curfs, M. Keuter, J. F. Meis, J. W. van der Meer. 1998. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J. Infect. Dis. 177:175.[Medline]
  16. Han, S. J., J. H. Choi, H. M. Ko, I. W. Choi, H. K. Lee, O. H. Lee, S. Y. Im. 1999. Glucocorticoids prevent NF-{kappa}B activation by inhibiting the early release of platelet-activating factor in response to LPS. Eur. J. Immunol. 29:1334.[Medline]
  17. Choi, I. H., Y. M. Shin, J. S. Park, M. S. Lee, E. H. Han, O. H. Chai, S. Y. Im, T. Y. Ha, H. K. Lee. 1998. Immunoglobulin E-dependent active fatal anaphylaxis in mast cell-deficient mice. J. Exp. Med. 188:1587.[Abstract/Free Full Text]
  18. Kravchenko, V. V., Z. Pan, J. Han, J. M. Herbert, R. J. Ulevitch, R. D. Ye. 1995. Platelet-activating factor induces NF-{kappa}B activation through a G protein-coupled pathway. J. Biol. Chem. 270:14928.[Abstract/Free Full Text]
  19. Smith, C. S., W. Y. Shearer. 1994. Activation of NF-{kappa}B and immunoglobulin expression in response to platelet-activating factor in a human B cell line. Cell. Immunol. 155:292.[Medline]
  20. Schieven, G. L., J. M. Kirihara, D. E. Myers, J. A. Ledbetter, F. M. Uckun. 1993. Reactive oxygen intermediates activate NF-{kappa}B in a tyrosine kinase dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes. Blood 82:1212.[Abstract/Free Full Text]
  21. Flohe, L., R. Brigelius-Flohe, C. Saliou, M. G. Traber, L. Packer. 1997. Redox regulation of NF-{kappa}B activation. Free Radical Biol. Med. 22:1115.[Medline]
  22. Choi, J. H., W. J. Chung, S. J. Han, H. B. Lee, I. H. Choi, H. K. Lee, K. Y. Jang, D. G. Lee, S. S. Han, K. H. Park, S. Y. Im. 2000. Selective involvement of reactive oxygen intermediates in platelet-activating factor-mediated activation of NF-{kappa}B. Inflammation 24:385.[Medline]
  23. Sano, M., K. Fukuda, H. Kodama, J. Pan, M. Saito, J. Matsuzaki, T. Takahashi, S. Makino, T. Kato, S. Ogawa. 2000. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J. Biol. Chem. 275:29717.[Abstract/Free Full Text]
  24. Frangogiannis, N. G., L. H. Mendoza, M. L. Lindsey, C. M. Ballantyne, L. H. Michael, C. W. Smith, M. L. Entman. 2000. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J. Immunol. 165:2798.[Abstract/Free Full Text]
  25. Smith, J. C., M. Magee, D. M. Williams, J. R. Graybill. 1990. Tumor necrosis factor-{alpha} plays a role in host defense against Histoplasma capsulatum. J. Infect. Dis. 162:1349.[Medline]
  26. Tracey, K. J., H. Vlassara, A. Cerami. 1989. Cachectin/tumor necrosis factor. Lancet 1:1122.[Medline]
  27. Netea, M. G., L. J. van Tits, J. H. Curfs, F. Amiot, J. F. Meis, J. W. van der Meer, B. J. Kullberg. 1999. Increased susceptibility of TNF-{alpha} lymphotoxin-{alpha} double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J. Immunol. 163:1498.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Cancer Res.Home page
K. Heon Seo, H.-M. Ko, H.-A Kim, J.-H. Choi, S. Jun Park, K.-J. Kim, H.-K. Lee, and S.-Y. Im
Platelet-Activating Factor Induces Up-regulation of Antiapoptotic Factors in a Melanoma Cell Line through Nuclear Factor-{kappa}B Activation.
Cancer Res., May 1, 2006; 66(9): 4681 - 4686.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Black, A. Wilson, and D. Samols
An Intact Phosphocholine Binding Site Is Necessary for Transgenic Rabbit C-Reactive Protein to Protect Mice against Challenge with Platelet-Activating Factor
J. Immunol., July 15, 2005; 175(2): 1192 - 1196.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. H. Seo, H.-S. Lee, B. Jung, H.-M. Ko, J.-H. Choi, S. J. Park, I.-H. Choi, H.-K. Lee, and S.-Y. Im
Estrogen Enhances Angiogenesis through a Pathway Involving Platelet-Activating Factor-Mediated Nuclear Factor-{kappa}B Activation
Cancer Res., September 15, 2004; 64(18): 6482 - 6488.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
I.-W. Choi, Y.-S. Kim, D.-K. Kim, J.-H. Choi, K.-H. Seo, S.-Y. Im, K.-S. Kwon, M.-S. Lee, T.-Y. Ha, and H.-K. Lee
Platelet-activating Factor-mediated NF-{kappa}B Dependency of a Late Anaphylactic Reaction
J. Exp. Med., July 7, 2003; 198(1): 145 - 151.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
J. D. Guida, A. M. Kunig, K. H. Leef, S. E. McKenzie, and D. A. Paul
Platelet Count and Sepsis in Very Low Birth Weight Neonates: Is There an Organism-Specific Response?
Pediatrics, June 1, 2003; 111(6): 1411 - 1415.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-J. Han, H.-M. Ko, J.-H. Choi, K. H. Seo, H.-S. Lee, E.-K. Choi, I.-W. Choi, H.-K. Lee, and S.-Y. Im
Molecular Mechanisms for Lipopolysaccharide-induced Biphasic Activation of Nuclear Factor-kappa B (NF-kappa B)
J. Biol. Chem., November 15, 2002; 277(47): 44715 - 44721.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, J. H.
Right arrow Articles by Im, S. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Choi, J. H.
Right arrow Articles by Im, S. Y.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS